Bacterial infection in neutropenic cancer patients: An overview

Iranian Journal of Clinical Infectious Diseases

Volumn 4, Issue 2, 2009, Pages 115-122

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CANCER PATIENT; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; MIXED INFECTION; PATIENT MONITORING; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 77953371508     PISSN: 17355109     EISSN: 20081081     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-51.
2. th edition, Hamilton, Ontario: BC Decker, Hamilton, Ontario. 2006;p:2222-45.
3. Rolston KVI. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40:S246-52.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10.
5. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-94.
6. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in cancer patients. Clin Infect Dis 2003;37:1144-45.
7. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr., Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402.
8. Kapadia M, Coyle E, Prince R, Rolston KVI. Declining in-vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. (Abstract # E-807) 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., Dec. 16-19, 2005.
9. Moise-Broder PA, Sakoulas G, Eliopoulos GM. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38;1700-5.
10. Safdar A, Rolston KVI. Vancomycin, tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 2006; 106:1815-20.
11. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine 1986;65:218-25.
12. Rolston KVI, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: An underappreciated and underreported entity. Clin Infect Dis 2007;45:228-33.
13. Rolston KVI, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of gram-positive bloodstream infections in patients with hematologic malignancies, and the in-vitro activity of various quinolones against gram-positive bacteria isolated from cancer patients. Int J Infect Dis 2006;10:223-30.
14. Goldman M, Chaudhary UB, Greist A, Fausel CA. Central nervous system infections due to Stomatococcus mucilaginosus in immunocompromised hosts. Clin Infect Dis 1998;27:1241-46.
15. Fanourgiakis P, Georgala A, Vekemans M, Daneau D, Heymans C, Aoun M. Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting of a cancer institute. Clin Microbiol Infect 2003;9:1068-72.
16. Rivero GA, Torres HA, Rolston KVI, Kontoyiannis DP. Listeria monocytogenes infection in patient with cancer. Diag Microbiol Infect Dis 2003;47: 393-98.
17. Weinstock DM, Brown AE. Rhodococcus equi: an emerging pathogen. Clin Infect Dis 2002;15:1379-85.
18. Han XY, Kamana M, Rolston KVI. Viridans streptococci isolated by culture from blood of cancer patients: Clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2006;44:160-65.
19. Kumashi P, Girgawy E, Tarrand J, Rolston KV, Raad II, Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: Disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine 2005; 84:303-12.
20. Matar MJ, Tarrand J, Raad I, Rolston KVI. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006;34:534-36.
21. Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients. Clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine 2007;86:69-77.
22. Bad bugs, no drugs. Infectious Diseases Society of America. July 2004.http://www.idsociety.org/pa/IDSA-Paper4-final-web.pdf).
23. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44(2):159-77.
24. Rolston KVI, Tarrand JJ. Pseudomonas aeruginosa; Still a frequent pathogen in patients with cancer: 11-year experience from a comprehensive cancer center. Clin Infect Dis 1999;29:463-64.
25. Rolston KVI, Kontoyiannis DP, Yadegarynia D, Raad I. Non-fermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diag Microbiol Infect Dis 2005;51:215-18.
26. Safdar A, Rolston KV. Stenotrophomonas maltophilia: Changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007;45:1602-9.
27. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32.
28. Aboufaycal H, Sader HS, Rolston K, Deshpande LM, Toleman M, Bodey G, et al. blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J Clin Microbiol 2007;45(2):614-5.
29. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al.; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection patients with cancer and neutropenia. N Engl J Med 2005;353(10):977-87.
30. Cullen M, Steven N, Billingham L, Gaunt Hastings M, Simmonds P, et al; Simple Investigation Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number Tumors (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353(10):988-98.
31. Gafter-Gvill A, Fraser A, Paul M, Liebovici Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
32. Segal BH, Freifeld AG, Baden LR. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122-74.
33. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 Suppl 1:S51-9.
34. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
35. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-51.
36. Feld R, Paesmans M, Freifeld AG, Klastersky Pizzo PA, Rolston KV, et al.; Immunocompromised Host Society; Multinational Association for Supportive Care in Cancer. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002;35(12):1463-8.
37. Kern KV. Risk assessment and treatment of lowrisk patients with febrile neutropenia. Clin Infect Dis 2006;15:533-40.
38. Rolston KVI. Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treatment Rev 2003;29:551-54.
39. Rolston K. New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515-21.
40. Talbot GH, Bradley J, Edwards JE, Jr., Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68.